SINGULAR GENOMICS SYSTEMS IN (OMIC)
US82933R3084 - Common Stock
OMIC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. OMIC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OMIC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
OMIC had negative earnings in the past year.
In the past year OMIC has reported a negative cash flow from operations.
OMIC had negative earnings in each of the past 5 years.
In the past 5 years OMIC always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -41.77%, OMIC is doing worse than 81.82% of the companies in the same industry.
OMIC's Return On Equity of -66.73% is on the low side compared to the rest of the industry. OMIC is outperformed by 76.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.77% | ||
| ROE | -66.73% | ||
| ROIC | N/A |
ROA(3y)-30.4%
ROA(5y)-41.68%
ROE(3y)-39.09%
ROE(5y)-60.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for OMIC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OMIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OMIC has been reduced compared to 1 year ago.
Compared to 1 year ago, OMIC has a worse debt to assets ratio.
2.2 Solvency
OMIC has an Altman-Z score of -2.96. This is a bad value and indicates that OMIC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.96, OMIC is doing worse than 87.27% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that OMIC is not too dependend on debt financing.
OMIC has a Debt to Equity ratio of 0.05. This is in the better half of the industry: OMIC outperforms 65.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.96 |
ROIC/WACCN/A
WACC10.49%
2.3 Liquidity
A Current Ratio of 8.77 indicates that OMIC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.77, OMIC belongs to the top of the industry, outperforming 87.27% of the companies in the same industry.
A Quick Ratio of 8.04 indicates that OMIC has no problem at all paying its short term obligations.
OMIC has a better Quick ratio (8.04) than 87.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.77 | ||
| Quick Ratio | 8.04 |
3. Growth
3.1 Past
OMIC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.41%.
The Revenue has grown by 27.10% in the past year. This is a very strong growth!
EPS 1Y (TTM)3.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.38%
Revenue 1Y (TTM)27.1%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%45.94%
3.2 Future
The Earnings Per Share is expected to grow by 9.60% on average over the next years. This is quite good.
OMIC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 108.16% yearly.
EPS Next Y9.67%
EPS Next 2Y8.48%
EPS Next 3Y9.6%
EPS Next 5YN/A
Revenue Next Year20.37%
Revenue Next 2Y96.92%
Revenue Next 3Y108.16%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
OMIC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OMIC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.48%
EPS Next 3Y9.6%
5. Dividend
5.1 Amount
No dividends for OMIC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SINGULAR GENOMICS SYSTEMS IN
NASDAQ:OMIC (11/4/2024, 8:27:57 PM)
After market: 22.2201 -0.09 (-0.4%)22.31
+8.85 (+65.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap55.77M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.77% | ||
| ROE | -66.73% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.77 | ||
| Quick Ratio | 8.04 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)3.41%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y9.67%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)27.1%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y